Novartis's $12B Avidity Deal Boosts Biotech Stocks and Neuroscience Pipeline
Novartis' CEO indicated that their $12 billion acquisition of Avidity BioSciences could have been twice as large, highlighting the significance of timing in deal-making.
Tag
Avidity Biosciences
All articles tagged with #avidity biosciences
Novartis Nears $12 Billion Deal to Acquire Avidity Biosciences
Novartis is acquiring Avidity Biosciences for about $12 billion to expand its portfolio in rare muscle disorders and strengthen its US presence, with Avidity's early-stage cardiology programs to be spun off into a new company, Spinco.
Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Neuroscience Pipeline
Novartis plans to acquire Avidity Biosciences for $12 billion to strengthen its neuroscience pipeline with late-stage RNA therapeutics targeting neuromuscular diseases, including a new platform for muscle-directed delivery of RNA therapies, aiming for product launches before 2030 and increasing its sales growth forecast to 6% CAGR for 2024-2029.
Novartis Approaches $12 Billion Acquisition of Avidity Biosciences
Novartis is set to acquire Avidity Biosciences for $12 billion, marking a significant move in the pharmaceutical industry.
Novartis to Acquire Avidity Biosciences for $12 Billion in Cash
Novartis is acquiring U.S. biotech firm Avidity Biosciences for about $12 billion in cash, aiming to expand its RNA therapeutics portfolio and boost growth, with the deal expected to close in the first half of 2026 after Avidity spins out some of its business units.
Novartis Nears $10 Billion Deal to Acquire Avidity Biosciences
Novartis is close to acquiring Avidity Biosciences for over $70 per share, in a deal potentially valued at around $6.8 billion, aiming to strengthen its portfolio amid a wave of biotech M&A and upcoming patent expirations.